Amalgamated Bank Decreases Position in Repligen Corporation (NASDAQ:RGEN)

Amalgamated Bank cut its position in Repligen Corporation (NASDAQ:RGEN) by 3.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 24,146 shares of the biotechnology company’s stock after selling 968 shares during the period. Amalgamated Bank’s holdings in Repligen were worth $3,072,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of RGEN. Signaturefd LLC raised its holdings in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after buying an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new position in Repligen in the fourth quarter worth about $29,000. Raiffeisen Bank International AG purchased a new position in Repligen in the fourth quarter worth about $29,000. Itau Unibanco Holding S.A. purchased a new position in Repligen in the fourth quarter worth about $40,000. Finally, Center for Financial Planning Inc. raised its holdings in Repligen by 110.3% in the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock worth $47,000 after buying an additional 193 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RGEN has been the subject of several recent analyst reports. Canaccord Genuity Group decreased their target price on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a report on Wednesday, April 16th. Wolfe Research upgraded shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price target for the company in a research note on Tuesday, April 29th. HC Wainwright reiterated a “buy” rating and issued a $180.00 price target on shares of Repligen in a research note on Monday, May 5th. Evercore ISI began coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price target for the company. Finally, Royal Bank Of Canada reduced their price target on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating for the company in a research note on Wednesday, April 30th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $172.83.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $127.36 on Friday. The firm has a 50 day moving average of $126.70 and a 200 day moving average of $139.96. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $7.16 billion, a price-to-earnings ratio of -283.02, a price-to-earnings-growth ratio of 3.65 and a beta of 1.11. Repligen Corporation has a 12-month low of $102.97 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.28 earnings per share. On average, research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.